secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kiniksa Pharmaceuticals International, plc (KNSA)
CIK:        0001730430
Form:       8-K
Filed at:   2022-05-03T23:59:59+00:00
Accession:  0001104659-22-055055
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiniksa Q1 2022 ARCALYST net revenue $22.2M; net loss narrows to $25.2M; FY2022 guidance $115-130M
--------------------------------------------------------------------------------

- ARCALYST net revenue $22.2M in Q1 2022 versus $0 in Q1 2021; total revenue $32.2M including $10M collaboration revenue.
- Net loss $25.2M, improved from $49.5M loss in Q1 2021; cash $145.6M, no debt.
- Full-year 2022 ARCALYST net revenue guidance $115M-$130M; cash expected to fund operations into at least 2024.
- Strategic collaboration with Huadong Medicine for Asia Pacific rights: $22M upfront, up to $640M milestones, tiered royalties.
- Over 400 prescribers for ARCALYST since launch; ~95% coverage approval; ~60% patients retained on therapy through Q1 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730430/000110465922055055/0001104659-22-055055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730430/000110465922055055/tm2214107d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-055055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer